Ixempra FDA Approval History
FDA Approved: Yes (First approved October 16, 2007)
Brand name: Ixempra
Generic name: ixabepilone
Dosage form: Injection
Company: R-Pharm US
Treatment for: Breast Cancer
Ixempra (ixabepilone) is a semisynthetic analog of epothilone B indicated for the treatment of patients with metastatic or locally advanced breast cancer.
Development timeline for Ixempra
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.